Hematopoietic stem cell mobilization for gene therapy: Superior mobilization by the combination of granulocyte-colony stimulating factor plus plerixafor in patients with β-thalassemia major

Human Gene Therapy

Volumn 24, Issue 10, 2013, Pages 852-860

  Yannaki, Evangelia ^a   Karponi, Garyfalia ^a   Zervou, Fani ^a   Constantinou, Varnavas ^a   Bouinta, Asimina ^a   Tachynopoulou, Varvara ^a   Kotta, Konstantina ^a   Jonlin, Erica ^b   Papayannopoulou, Thalia ^b   Anagnostopoulos, Achilles ^a   Stamatoyannopoulos, George ^b  

^a G PAPANICOLAOU HOSPITAL   (Greece)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; DEFERIPRONE; GRANULOCYTE COLONY STIMULATING FACTOR; PLACEBO; PLERIXAFOR;

ADULT; APHERESIS; ARTICLE; CD34 SELECTION; CELL ASSAY; CLINICAL ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLOW CYTOMETRY; GENE THERAPY; HUMAN; HUMAN CELL; LABORATORY DEVICE; LEUKAPHERESIS; LEUKOCYTOSIS; MALE; PHENOTYPE; SPLENECTOMY; STEM CELL; STEM CELL GENE THERAPY; STEM CELL MOBILIZATION; TARGET CELL; THALASSEMIA MAJOR; TREATMENT OUTCOME;

ADULT; ANTIGENS, CD34; BETA-THALASSEMIA; COLONY-FORMING UNITS ASSAY; COMBINED MODALITY THERAPY; FEMALE; GENETIC THERAPY; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HETEROCYCLIC COMPOUNDS; HUMANS; MALE; PHENOTYPE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84885410660     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2013.163     Document Type: Article

References (35)

1. Abboud, M., Laver, J., and Blau, C.A. (1998). Granulocytosis causing sickle-cell crisis. Lancet 351, 959.
2. Adler, B.K., Salzman, D.E., Carabasi, M.H., et al. (2001). Fatal sickle cell crisis after granulocyte colony-stimulating factor administration. Blood 97, 3313-3314.
3. Aiuti, A., Cattaneo, F., Galimberti, S., et al. (2009). Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N. Engl. J. Med. 360, 447-458.
4. Aiuti, A., Biasco, L., Scaramuzza, S., et al. (2013). Lentiviral he-matopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science 341, 1233151.
5. Anderlini, P., Przepiorka, D., Seong, C., et al. (1997). Factors affecting mobilization of CD34+ cells in normal donors treated with filgrastim. Transfusion 37, 507-512.
6. Bensinger, W.I., Martin, P.J., Storer, B., et al. (2001). Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hemato-logic cancers. N. Engl. J. Med. 344, 175-181.
7. Biffi, A., Montini, E., Lorioli, L., et al. (2013). Lentiviral hemato-poietic stem cell gene therapy benefits metachromaticleuko-dystrophy. Science 341, 1233158.
8. Boztug, K., Schmidt, M., Schwarzer, A., et al. (2010). Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N. Engl. J. Med. 363, 1918-1927.
9. Broxmeyer, H.E., Orschell, C.M., Clapp, D.W., et al. (2005). Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J. Exp. Med. 201, 1307-1318.
10. Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C.C., et al. (2009). Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326, 818-823.
11. Cavazzana-Calvo, M., Hacein-Bey, S., de Saint Basile, G., et al. (2000). Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288, 669-72.
12. Cavazzana-Calvo, M., Payen, E., Negre, O., et al. (2010). Transfusion independence and HMGA2 activation after gene therapy of human b-thalassaemia. Nature 467, 318-322.
13. Croop, J.M., Cooper, R., Fernandez, C., et al. (2001). Mobilization and collection of peripheral blood CD34 + cells from patients with Fanconi anemia. Blood 98, 2917-2921.
14. De Odorico, I., Spaulding, K., Pretorius, D., et al. (1999). Normal splenic volumes estimated using three-dimensional ultraso-nography. J. Ultrasound Med.18, 231-236.
15. Devine, S.M., Flomenberg, N., Vesole, D.H., et al. (2004). Rapid mobilization of CD34 + cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J. Clin. Oncol. 22, 1095-1102.
16. Devine, S.M., Vij, R., Rettig, M., et al. (2008). Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood 112, 990-998.
17. DiPersio, J.F., Micallef, I.N., Stiff, P.J., et al. (2009). Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J. Clin. Oncol. 27, 4767-4773.
18. Eldor, A., and Rachmilewitz, E.A. (2002). The hypercoagulable state in thalassemia. Blood 99, 36-43.
19. Falzetti, F., Aversa, F., Minelli, O., and Tabilio, A. (1999). Spontaneous rupture of spleen during peripheral blood stem-cell mobilisation in a healthy donor. Lancet 353, 555.
20. Fruehauf, S., Veldwijk, M.R., Seeger, T., et al. (2009). A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study. Cytotherapy 11, 992-1001.
21. Gratwohl, A., Baldomero, H., Schmid, O., et al. (2005). Change in stem cell source for hematopoietic stem cell transplantation (HSCT) in Europe: a report of the EBMT activity survey 2003. Bone Marrow Transplant. 36, 575-590.
22. Hill, J.M., Syed, M.A., Arai, A.E., et al. (2005). Outcomes and risks of granulocyte colony-stimulating factor in patients with coronary artery disease. J. Am. Coll. Cardiol. 46, 1643-1648.
23. Kelly, P.F., Radtke, S., von Kalle, C., et al. (2007). Stem cell collection and gene transfer in Fanconianemia. Mol. Ther. 15, 211-219.
24. Liles, W.C., Broxmeyer, H.E., Rodger, E., et al. (2003). Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 102, 2728-2730.
25. Liles, W.C., Rodger, E., Broxmeyer, H.E., et al. (2005). Augmented mobilization and collection of CD34 + hematopoi-etic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion 45, 295-300.
26. Miller, J.P., Perry, E.H., Price, T.H., et al. (2008). Recovery and safety profiles of marrow and PBSC donors: experience of the National Marrow Donor Program. Biol. Blood Marrow Transplant. 14, 29-36.
27. Nademanee, A.P., DiPersio, J.F., Maziarz, R.T., et al. (2012). Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34( + ) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial. Biol Blood Marrow Transplant. 18, 1564-1572.
28. Ott, M.G., Schmidt, M., Schwarzwaelder, K., et al. (2006). Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat. Med. 12, 401-409.
29. Russell, N.H., Hunter, A., Rogers, S., et al. (1993). Peripheral blood stem cells as an alternative to marrow for allogeneic transplantation. Lancet 341, 1482.
30. Sadelain, M., Rivière, I., Wang, X., et al. (2010). Strategy for a multicenter phase I clinical trial to evaluate globin gene transfer in beta-thalassemia. Ann. N. Y. Acad. Sci. 1202, 52-58.
31. Stiff, P., Gingrich, R., Luger, S., et al. (2000). A randomized phase 2 study of PBPC mobilization by stem cell factor and fil-grastim in heavily pretreated patients with Hodgkin's disease or non-Hodgkin's lymphoma. Bone Marrow Transplant. 26, 471-481.
32. To, L.B., Haylock, D.N., Simmons, P.J., and Juttner, C.A. (1997). The biology and clinical uses of blood stem cells. Blood 89, 2233-2258.
33. To, L.B., Levesque, J.P., and Herbert, K.E. (2011). How I treat patients who mobilize hematopoietic stem cells poorly. Blood 118, 4530-4540.
34. Yannaki, E., Emery, D.W., and Stamatoyannopoulos, G. (2010). Gene therapy for b-thalassaemia: the continuing challenge. Expert Rev. Mol. Med. 12, e31.
35. Yannaki, E., Papayannopoulou, T., Jonlin, E., et al. (2012). He-matopoietic stem cell mobilization for gene therapy of adult patients with severe b-thalassemia: results of clinical trials using G-CSF or plerixafor in splenectomized and non-splenectomized subjects. Mol. Ther. 20, 230-238.